Company: LENZ
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001815776-25-000019
Chunk: 30

Company: LENZ Therapeutics, Inc.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 9B
Chunk 30
---
mital Shah(7)12,500 — — 12,500 Jo Viney(7)11,250 — — 11,250 

__________________

(1)In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2024, computed in accordance with FASB ASC Topic 718, Compensation—Stock Compensation. These amounts do not reflect the actual economic value that will be realized by the director upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options.

(2)As of December 31, 2024, Mr. George holds outstanding options to purchase 27,000 shares.

(3)As of December 31, 2024, Dr. Guerard holds outstanding options to purchase 81,468 shares.

(4)As of December 31, 2024, Mr. McCollum holds outstanding options to purchase 27,000 shares.

(5)As of December 31, 2024, Ms. Thunen holds outstanding options to purchase 27,000 shares.

(6)As of December 31, 2024, Dr. Scheiner holds outstanding options to purchase 27,000 shares.

(7)Resigned from the board of directors on March 21, 2024, effective as of the effective time of the Merger.

(8)Dr. Porteus received compensation from Graphite under a consulting agreement.

Insider Trading Policy

We have adopted an insider trading policy governing the purchase, sale, and/or other dispositions of our securities and those of public companies in which we have a business relationship by our directors, executive officers, employees and independent contractors, contingent workers and consultants, that we believe is reasonably designed to promote compliance 

136

Table of Contents

with insider trading laws, rules and regulations, and the exchange listing standards applicable to us. It is our policy that any transactions in LENZ securities by the company itself shall be in full compliance with insider trading laws, rules and regulations. A copy of our insider trading policy, including any amendments thereto, is filed as Exhibit 19.1 to this Annual Report on Form 10-K.

Item 11. Executive Compensation 

To achieve our goals, we have designed, and intend to modify as necessary, our compensation and benefits program to attract, retain, incentivize and reward deeply talented and qualified executives who share